BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12723557)

  • 1. EANM procedure guidelines for treatment of refractory metastatic bone pain.
    Silberstein EB; Taylor AT;
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP7-11. PubMed ID: 12723557
    [No Abstract]   [Full Text] [Related]  

  • 2. EANM procedure guidelines for radiosynovectomy.
    Clunie G; Fischer M;
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP12-6. PubMed ID: 12723558
    [No Abstract]   [Full Text] [Related]  

  • 3. Pain palliation and nuclear medicine.
    McEwan AJ
    Eur J Nucl Med; 1993 Jan; 20(1):1-3. PubMed ID: 7678395
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted radionuclide therapy for bone metastases.
    Lewington VJ
    Eur J Nucl Med; 1993 Jan; 20(1):66-74. PubMed ID: 7678397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-186 HEDP treatment in breast cancer patients with bone metastases.
    Koutsikos J; Leondi A
    J Natl Med Assoc; 2008 Apr; 100(4):447. PubMed ID: 18481487
    [No Abstract]   [Full Text] [Related]  

  • 6. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
    Han SH; De Klerk JM; Zonnenberg BA; Tan S; Van Rijk PP
    Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of rhenium-188 HEDP in bone metastases therapy.
    Scheffler J; Derejko M; Bandurski T; Romanowicz G
    Nucl Med Rev Cent East Eur; 2003; 6(1):55-7. PubMed ID: 14600935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in our understanding of the treatment of painful bone metastasis.
    Siberstein EB
    J Nucl Med; 2000 Apr; 41(4):655-7. PubMed ID: 10809605
    [No Abstract]   [Full Text] [Related]  

  • 9. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
    Maxon HR; Schroder LE; Hertzberg VS; Thomas SR; Englaro EE; Samaratunga R; Smith H; Moulton JS; Williams CC; Ehrhardt GJ
    J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
    Scher HI; Curley T; Yeh S; Tong W; O'Moore PV; Larson S
    Adv Exp Med Biol; 1992; 324():115-29. PubMed ID: 1283494
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases.
    Koutsikos J; Leondi A
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1392-3; author reply 1394-5. PubMed ID: 18438661
    [No Abstract]   [Full Text] [Related]  

  • 12. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group.
    Piffanelli A; Dafermou A; Giganti M; Colamussi P; Pizzocaro C; Bestagno M;
    Q J Nucl Med; 2001 Mar; 45(1):100-7. PubMed ID: 11456368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
    Brenner W; Kampen WU; Kampen AM; Henze E
    J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palliative therapy with rhenium-186-HEDP for bone metastases of breast cancer.
    Guerra UP; Englaro E; Cattaruzzi E
    Tumori; 1997; 83(2):560-2. PubMed ID: 9226021
    [No Abstract]   [Full Text] [Related]  

  • 15. 186Re-HEDP for metastatic bone pain in breast cancer patients.
    Lam MG; de Klerk JM; van Rijk PP
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
    Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
    J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unsealed source therapy of painful bone metastases: an update.
    McEwan AJ
    Semin Nucl Med; 1997 Apr; 27(2):165-82. PubMed ID: 9144858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
    Jong JM; Oprea-Lager DE; Hooft L; de Klerk JM; Bloemendal HJ; Verheul HM; Hoekstra OS; van den Eertwegh AJ
    Eur Urol; 2016 Sep; 70(3):416-26. PubMed ID: 26391636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 186Re-etidronate in breast cancer patients with metastatic bone pain.
    Han SH; Zonneberg BA; de Klerk JM; Quirijnen JM; van het Schip AD; van Dijk A; Blijham GH; van Rijk PP
    J Nucl Med; 1999 Apr; 40(4):639-42. PubMed ID: 10210223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation.
    Strigari L; Sciuto R; D'Andrea M; Pasqualoni R; Benassi M; Maini CL
    Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1031-8. PubMed ID: 17237963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.